Nanomedicine-based delivery strategies for nucleic acid gene inhibitors in inflammatory diseases

[Display omitted] Thanks to their abilities to modulate the expression of virtually any genes, RNA therapeutics have attracted considerable research efforts. Among the strategies focusing on nucleic acid gene inhibitors, antisense oligonucleotides and small interfering RNAs have reached advanced cli...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2021-08, Vol.175, p.113809-113809, Article 113809
Main Authors: Fattal, Elias, Fay, François
Format: Article
Language:English
Subjects:
Animals
Anti-Inflammatory Agents - administration & dosage
Anti-Inflammatory Agents - therapeutic use
Drug Delivery Systems - methods
Galenic pharmacology
Gene inhibition
Genes - drug effects
Humans
Inflammation
Inflammation - drug therapy
Inflammation - genetics
Life Sciences
Nanomedicine - methods
Nanoparticle
Nanoparticle Drug Delivery System
Nucleic acid
Nucleic Acids - administration & dosage
Nucleic Acids - therapeutic use
Oligodeoxyribonucleotides, Antisense - administration & dosage
Oligodeoxyribonucleotides, Antisense - therapeutic use
Pharmaceutical sciences
RNA, Small Interfering - administration & dosage
RNA, Small Interfering - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Thanks to their abilities to modulate the expression of virtually any genes, RNA therapeutics have attracted considerable research efforts. Among the strategies focusing on nucleic acid gene inhibitors, antisense oligonucleotides and small interfering RNAs have reached advanced clinical trial phases with several of them having recently been marketed. These successes were obtained by overcoming stability and cellular delivery issues using either chemically modified nucleic acids or nanoparticles. As nucleic acid gene inhibitors are promising strategies to treat inflammatory diseases, this review focuses on the barriers, from manufacturing issues to cellular/subcellular delivery, that still need to be overcome to deliver the nucleic acids to sites of inflammation other than the liver. Furthermore, key examples of applications in rheumatoid arthritis, inflammatory bowel, and lung diseases are presented as case studies of systemic, oral, and lung nucleic acid delivery.
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2021.05.019